Clinical Performance of Pharmacological Treatments for Alzheimer’s Disease: Impact on Cognitive Decline¿Te fue útil esta conversación hasta ahora?

Authors

DOI:

https://doi.org/10.5281/zenodo.24285816

Keywords:

Alzheimer Disease, Cognitive Dysfunction, Cholinesterase Inhibitors, Antibodies Monoclonal, Treatment Outcome

Abstract

Introduction: Cognitive impairment is the core manifestation of Alzheimer’s disease (AD). Its pharmacological management is transitioning from symptomatic treatments toward antibodies intended to modify the course of the disease, challenging the criteria used to assess the clinical performance of a drug. Methods: A literature review was conducted. A total of 318 records were identified in Web of Science and Scopus (2023-2026, open access). After removing duplicates, screening abstracts, and reviewing full-text articles, 35 studies were included. Results: Acetylcholinesterase inhibitors showed limited cognitive improvement (standardized mean differences ranging from -0.33 to -0.65), sustained in real-world clinical practice for up to four years. Anti-amyloid antibodies slowed cognitive and functional decline (CDR-SB differences ranging from -0.45 to -0.7 points compared with placebo), below the minimum clinically important difference thresholds reported for early AD (1.5 to 2.12 points). These treatments were associated with an elevated risk of amyloid-related imaging abnormalities, and their benefits were conditional on disease stage and ApoE4 genotype. Emerging molecules yielded predominantly exploratory results. Drugs for agitation did not report cognitive outcomes. Discussion: Improving and slowing decline are distinct approaches to managing cognitive impairment; therefore, network comparisons that combine them produce unstable hierarchies. Some conclusions were found to extend beyond the aggregated data, and developer pharmaceutical companies were frequently involved in the analyses. Conclusion: Therapeutic decisions for cognitive impairment require integrating the type and magnitude of treatment effect, safety burden, and treatment window of applicability of each drug, rather than relying primarily on statistical significance.

Downloads

Download data is not yet available.

References

1. Gorin BI, Pozdnyakov SO, Potapova KA, Tukhovskaya EA, Gorchakov DS. Efficacy and safety of DMB-I (latrepirdine) therapy in mild to moderate dementia in Alzheimer's disease: results of a multicenter, double-blind, randomized, placebo-controlled, clinical trial in three parallel groups. Scientific Reports [Internet]. 2026 [citado el 15 de octubre de 2026];16(1). Disponible en: https://doi.org/10.1038/s41598-026-49538-4

2. Albertyn CP, Guu TW, Chu PTA, Creese B, Young A, Velayudhan L, et al. Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial. Age and Ageing [Internet]. 2025 [citado el 15 de octubre de 2026];54(6). Disponible en: https://doi.org/10.1093/ageing/afaf149

3. Zurek M, Wierzbinski P. Treatment of dementia syndromes using modern transdermal delivery systems. Psychiatria i Psychologia Kliniczna-Journal of Psychiatry and Clinical Psychology [Internet]. 2026 [citado el 15 de octubre de 2026];26(1). Disponible en: https://doi.org/10.15557/PiPK.2026.0010

4. Gao YQ, Liu YL, Li YF. Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis. Advances in Clinical and Experimental Medicine [Internet]. 2024 [citado el 15 de octubre de 2026];33(11). Disponible en: https://doi.org/10.17219/acem/176051

5. Lecerf S, Guinebretiere O, Bentegeac R, Gauthier V, Aymes E, Mekkaoui C, et al. Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study. Lancet Regional Health-Europe [Internet]. 2026 [citado el 15 de octubre de 2026];62. Disponible en: https://doi.org/10.1016/j.lanepe.2026.101607

6. Lim S, Lee HW, Yoon S, Han JW, Chung JY, Yoon S. Sex differences in efficacy/safety of anti-amyloid-beta monoclonal antibodies for the treatment of Alzheimer's disease. Translational and Clinical Pharmacology [Internet]. 2025 [citado el 15 de octubre de 2026];33(4). Disponible en: https://doi.org/10.12793/tcp.2025.33.e19

7. Shim GH, Lau ECY, Huynh ALH, Lu CY, Tan ECK. Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis. Ageing Research Reviews [Internet]. 2026 [citado el 15 de octubre de 2026];114. Disponible en: https://doi.org/10.1016/j.arr.2025.102981

8. Liu SY, Zhao M, Liu Y, Yang X, Yan HY, Xu HC, et al. Comparative efficacy and safety of symptomatic therapy and disease-modifying therapy for Alzheimer's disease: a systematic review and network meta-analysis. Frontiers in Neuroscience [Internet]. 2025 [citado el 15 de octubre de 2026];19. Disponible en: https://doi.org/10.3389/fnins.2025.1656906

9. Kalampokini S, Keramidiotis I, Frontistis A, Zuchi F, Michmizos D, Papaliagkas V, et al. Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review. Journal of Clinical Medicine [Internet]. 2026 [citado el 15 de octubre de 2026];15(17). Disponible en: https://doi.org/10.3390/jcm15176782

10. Xing BK, Yang JR, Hua H, Jiang R. Rapid health technology assessment of galantamine for the treatment of Alzheimer's disease A review. Medicine [Internet]. 2025 [citado el 15 de octubre de 2026];104(23). Disponible en: https://doi.org/10.1097/MD.0000000000042744

11. Ribas GG, Ferrer-Picón E. Tolerability of rivastigmine transdermal patch in patients with Alzheimer's disease: a narrative review. Expert Opinion on Drug Safety [Internet]. 2026 [citado el 15 de octubre de 2026];25(4). Disponible en: https://doi.org/10.1080/14740338.2025.2576520

12. Su CH, Chang YT, Tseng HS, Kuo CY, Chen JH, Chiena PY, et al. Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials. Clinical Medicine [Internet]. 2025 [citado el 15 de octubre de 2026];25(4). Disponible en: https://doi.org/10.1016/j.clinme.2025.100336

13. Deng XY, Li DS. Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis. Medicine [Internet]. 2024 [citado el 15 de octubre de 2026];103(38). Disponible en: https://doi.org/10.1097/MD.0000000000039753

14. Wang HY, Pan JY, Zhang MM, Tan ZD. Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease. Frontiers in Pharmacology [Internet]. 2025 [citado el 15 de octubre de 2026];16. Disponible en: https://doi.org/10.3389/fphar.2025.1599048

15. Qiao Y, Chi YW, Zhang QY, Ma Y. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. Frontiers in Aging Neuroscience [Internet]. 2023 [citado el 15 de octubre de 2026];15. Disponible en: https://doi.org/10.3389/fnagi.2023.1169499

16. Chowdhury S, Chowdhury NS. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review. International Journal of Immunopathology and Pharmacology [Internet]. 2023 [citado el 15 de octubre de 2026];37. Disponible en: https://doi.org/10.1177/03946320231209839

17. Van Dyck CH, Sperling R, Johnson K, Dhadda S, Kanekiyo M, Li DV, et al. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study. Alzheimers & Dementia [Internet]. 2025 [citado el 15 de octubre de 2026];21(12). Disponible en: https://doi.org/10.1002/alz.70905

18. Chen SH, Ou RW, Wei QQ, Li CY, Song W, Zhao B, et al. Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China. Alzheimers & Dementia [Internet]. 2025 [citado el 15 de octubre de 2026];21(10). Disponible en: https://doi.org/10.1002/alz.70750

19. Rashad A, Rasool A, Shaheryar M, Sarfraz A, Sarfraz Z, Robles-Velasco K, et al. Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials. Healthcare [Internet]. 2023 [citado el 15 de octubre de 2026];11(1). Disponible en: https://doi.org/10.3390/healthcare11010032

20. Khartabil N, Awaness A. Targeting Amyloid Pathology in Early Alzheimer's: The Promise of Donanemab-Azbt. Pharmacy [Internet]. 2025 [citado el 15 de octubre de 2026];13(1). Disponible en: https://doi.org/10.3390/pharmacy13010023

21. Jessen F, Dell'Agnello G, Zimmer JA, Sapin C, Dichter S, Doty E, et al. Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses. JPAD-Journal of Prevention of Alzheimers Disease [Internet]. 2026 [citado el 15 de octubre de 2026];13(8). Disponible en: https://doi.org/10.1016/j.tjpad.2026.100605

22. Brookfield N, Hauck PM, Doty EG, Zimmer JA, Yang F, Chen YF, et al. Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for APOE ε4. Neurodegenerative Disease Management [Internet]. 2026 [citado el 15 de octubre de 2026]. Disponible en: https://doi.org/10.1080/17582024.2026.2723524

23. Elamin SA, Al Shibli AN, Shaito A, Al-Maadhadi MJMB, Zolezzi M, Pedersen S. Anti-amyloid monoclonal antibody therapies in Alzheimer's disease - a scoping review. Neuroscience [Internet]. 2025 [citado el 15 de octubre de 2026];589. Disponible en: https://doi.org/10.1016/j.neuroscience.2025.10.011

24. Mostafa A, Tiu S, Khan F, Baig NA. The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer's Dementia: A Systematic Review. Annals of Indian Academy of Neurology [Internet]. 2025 [citado el 15 de octubre de 2026];28(3). Disponible en: https://doi.org/10.4103/aian.aian_547_24

25. Shahid K, Tamene Y, Mody SP, Sadiq KO, Shivakumar YM, Burra E, et al. Comparative Study of Safety and Efficacy of Angiotensin-Receptor Blockers and Anti Amyloid-β Monoclonal Antibodies for the Treatment of Alzheimer's Disease: A Systematic Review. Cureus Journal of Medical Science [Internet]. 2023 [citado el 15 de octubre de 2026];15(8). Disponible en: https://doi.org/10.7759/cureus.43984

26. Pascual-Lucas M, Lacosta AM, Montañés M, Canudas J, Loscos J, Monleón I, et al. Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study. Alzheimers & Dementia [Internet]. 2025 [citado el 15 de octubre de 2026];21(10). Disponible en: https://doi.org/10.1002/alz.70776

27. Cai WT, Zhang H, Wu Y, Yao Y, Zhang JP. Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Aging Neuroscience [Internet]. 2025 [citado el 15 de octubre de 2026];16. Disponible en: https://doi.org/10.3389/fnagi.2024.1465871

28. Wunderlich G, Blahova Z, Garcia M, Jessen F. Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer's dementia: a randomized controlled trial. Alzheimers Research & Therapy [Internet]. 2023 [citado el 15 de octubre de 2026];15(1). Disponible en: https://doi.org/10.1186/s13195-023-01163-3

29. Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, et al. A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease. JPAD-Journal of Prevention of Alzheimers Disease [Internet]. 2025 [citado el 15 de octubre de 2026];12(9). Disponible en: https://doi.org/10.1016/j.tjpad.2025.100337

30. Erichsen JM, Register TC, Sutphen C, Ma D, Gaussoin SA, Rudolph M, et al. A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD. Alzheimers & Dementia [Internet]. 2025 [citado el 15 de octubre de 2026];21(10). Disponible en: https://doi.org/10.1002/alz.70704

31. Fernandes JVA, Ramos JVD, Vilar LAD, Holanda MMD. Brexpiprazole for agitation in alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Psychiatry [Internet]. 2025 [citado el 15 de octubre de 2026];67(9). Disponible en: https://doi.org/10.4103/indianjpsychiatry_197_25

32. Zhong K, Cummings J. A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease. Expert Review of Neurotherapeutics [Internet]. 2025 [citado el 15 de octubre de 2026];25(1). Disponible en: https://doi.org/10.1080/14737175.2024.2407836

33. Stroud J, Cummings JL, Chumki SR, Such P, Wang DV, Palma AM, et al. Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease. Current Medical Research and Opinion [Internet]. 2025 [citado el 15 de octubre de 2026];41(8). Disponible en: https://doi.org/10.1080/03007995.2025.2552278

34. Tariot PN, Chumki SR, Wang D, Such P, Palma AM, Zhang Z, et al. Brexpiprazole for Agitation in Patients with Alzheimer's Dementia with and without Co-Occurring Psychosis: Post Hoc Analysis of Short- and Long-Term Trials. Neuropsychiatric Disease and Treatment [Internet]. 2026 [citado el 15 de octubre de 2026];22. Disponible en: https://doi.org/10.2147/NDT.S586701

35. Nakamura Y, Adachi J, Hirota N, Iba K, Shimizu K, Nakai M, et al. Long-term safety and tolerability of brexpiprazole for Japanese patients with agitation in Alzheimer's disease dementia: A multicenter, open-label study. Journal of Alzheimers Disease Reports [Internet]. 2025 [citado el 15 de octubre de 2026];9. Disponible en: https://doi.org/10.1177/25424823251334054

Published

2026-11-16

Issue

Section

Investigación Cualitativa

How to Cite

Morales Vergara, J., Acosta Nieto, A., Leon Morales, F., González Berrios, P., Fernandez Cibils, J., Gómez Carvajal, F., & Villalobos Tarqui, B. (2026). Clinical Performance of Pharmacological Treatments for Alzheimer’s Disease: Impact on Cognitive Decline¿Te fue útil esta conversación hasta ahora?. Revista Andes, 2(3), 25-36. https://doi.org/10.5281/zenodo.24285816

Most read articles by the same author(s)

Similar Articles

1-10 of 37

You may also start an advanced similarity search for this article.